Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SIRT1 | Q96EB6 | 2/20 | 0.44 |
| ▸ | SIRT2 | Q8IXJ6 | 1/20 | 0.44 |
| ▸ | TSHR | P16473 | 2/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.42 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.42 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.41 |
| ▸ | BRD4 | O60885 | 2/20 | 0.41 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.41 |
| ▸ | MEN1 | O00255 | 1/20 | 0.41 |
| ▸ | SCN9A | Q15858 | 1/20 | 0.41 |
| ▸ | CCKBR | P32239 | 1/20 | 0.40 |
| ▸ | PLA2G10 | O15496 | 1/20 | 0.40 |
| ▸ | PLA2G5 | P39877 | 1/20 | 0.40 |
| ▸ | ACE | P12821 | 1/20 | 0.40 |
| ▸ | HPGD | P15428 | 1/20 | 0.39 |
| ▸ | MTNR1A | P48039 | 2/20 | 0.39 |
| ▸ | MTNR1B | P49286 | 2/20 | 0.39 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.39 |
| ▸ | PREP | P48147 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9198952 | 1.00 | SIRT1 (0.44) | SIRT1SIRT2TSHRALDH1A1MAPK1 | |
| SCHEMBL9202863 | 0.79 | GPR119 (0.40) | TSHRCCKBRHPGD | |
| SCHEMBL9206852 | 0.75 | GBA1 (0.43) | ALDH1A1KMT2AL3MBTL1MEN1PLA2G10 | |
| SCHEMBL11197364 | 0.75 | MMP13 (0.53) | SIRT1SIRT2TSHRALDH1A1MAPK1 | |
| SCHEMBL6160063 | 0.74 | KMT2A (0.43) | TSHRALDH1A1MAPK1KMT2AL3MBTL1 | |
| SCHEMBL6160727 | 0.74 | KMT2A (0.43) | TSHRALDH1A1MAPK1KMT2AL3MBTL1 | |
| SCHEMBL27737512 | 0.74 | HPGD (0.45) | HPGDSMN1; SMN2 | |
| SCHEMBL6160007 | 0.74 | KMT2A (0.41) | SIRT1SIRT2TSHRALDH1A1MAPK1 | |
| SCHEMBL6160730 | 0.74 | KMT2A (0.43) | TSHRALDH1A1MAPK1KMT2AL3MBTL1 | |
| SCHEMBL9209222 | 0.74 | CCKBR (0.75) | CCKBR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-1518450-A | Use of adenosine analogues for the preparation of a medicament for the treatment of insulin resistance syndrome and diabetes | ���ĵ�˹ҩ��¹�����˾ | 2004-08-04 | — | — | CN | disclosed |
| EP-1404338-A1 | ADENOSINE ANALOGUES FOR THE TREATMENT OF THE INSULIN RESISTANCE SYNDROME AND DIABETES | Aventis Pharma Deutschland GmbH (DE) | 2004-04-07 | — | — | EP | disclosed |
| US-20030176390-A1 | Methods of treating insulin resistance syndrome and diabetes | HERLING ANDREAS (DE) | 2003-09-18 | — | — | US | disclosed |
| EP-0912520-B1 | COMPOUNDS HAVING ANTIHYPERTENSIVE, CARDIOPROTECTIVE, ANTI-ISCHEMIC AND ANTILIPOLYTIC PROPERTIES | AVENTIS PHARM PROD INC (US) | 2003-05-07 | — | — | EP | disclosed |
| US-6559313-B2 | Adenosine derivatives such as (1S,2R,3S,4R)-2,3-dihydroxy-4-(6-(1-(4-trifluormethylpyridin-2-yl)pyrrolidin-3(S)-yl-amino)purin-9-yl)cyclopentanecarboxylic acid isopropylamide | AVENTIS PHARMA DEUTSCHLAND GMBH (DE) | 2003-05-06 | — | — | US | disclosed |
| WO-2002092093-A1 | ADENOSINE ANALOGUES FOR THE TREATMENT OF THE INSULIN RESISTANCE SYNDROME AND DIABETES | AVENTIS PHARMA DEUTSCHLAND GMBH (DE) | 2002-11-21 | — | — | WO | disclosed |
| EP-1258247-A1 | Adenosine analogues for the treatment of insulin resistance syndrome and diabetes | Aventis Pharma Deutschland GmbH (DE) | 2002-11-20 | — | — | EP | disclosed |
| US-20020099030-A1 | Compounds having antihypertensive, cardioprotective anti-ischemic and antilipolytic properties | AVENTIS PHARMA DEUTSCHLAND GMBH (DE) | 2002-07-25 | — | — | US | disclosed |
| US-6376472-B1 | N6-SUBSTITUTED ADENOSINES | AVENTIS PHARMACEUTICALS, INC. | 2002-04-23 | — | — | US | disclosed |
| WO-2000023447-A1 | ADENOSINE ANALOGUES HAVING ANTIHYPERTENSIVE, CARDIOPROTECTIVE, ANTI-ISCHEMIC ANTILIPOLYTIC PROPERTIES | AVENTIS PHARMACEUTICALS PRODUCTS INC. (US) | 2000-04-27 | — | — | WO | disclosed |
| EP-0912520-A4 | COMPOUNDS HAVING ANTIHYPERTENSIVE, CARDIOPROTECTIVE, ANTI-ISCHEMIC AND ANTILIPOLYTIC PROPERTIES | RHONE POULENC RORER PHARMA (US) | 1999-10-06 | — | — | EP | disclosed |
| EP-0912520-A1 | COMPOUNDS HAVING ANTIHYPERTENSIVE, CARDIOPROTECTIVE, ANTI-ISCHEMIC AND ANTILIPOLYTIC PROPERTIES | RHONE-POULENC RORER PHARMACEUTICALS, INC. (US) | 1999-05-06 | — | — | EP | disclosed |
| WO-1998001426-A1 | COMPOUNDS HAVING ANTIHYPERTENSIVE, CARDIOPROTECTIVE, ANTI-ISCHEMIC AND ANTILIPOLYTIC PROPERTIES | RHONE-POULENC RORER PHARMACEUTICALS INC. (US) | 1998-01-15 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030176390-A1 | Methods of treating insulin resistance syndrome and diabetes | IAPP, GPR119, INSR | SIRT1 118/4885SIRT2 800/4885TSHR 1927/4885 |
| US-20020099030-A1 | Compounds having antihypertensive, cardioprotective anti-ischemic and antilipolytic properties | HMGCR, TGFB1, APOB | SIRT1 387/4885SIRT2 1054/4885TSHR 4041/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.